Undervalued Drug Manufacturer Stocks on NYS June 2025

June 28, 2025

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

New York Stock Exchange

The New York Stock Exchange, located in New York City, is the largest securities exchange in the world by market capitalization of its listed companies.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
MRK Merck & Co 76.84 154.49 101.06 14498141 194482 4.11 11.2
OGN Organon 9.22 14.97 62.34 8705781 2406 9.33 3.2
JNJ Johnson & Johnson 155.21 185.41 19.46 8295754 376198 3.23 17.3
ZTS Zoetis 168.63 199.90 18.54 3210485 75546 1.11 30.3
ELAN Elanco Animal Health 13.44 15.46 15.01 7194510 6708 0.00 17.9
RDY Dr Reddy's Laboratories 14.72 16.53 12.28 1557780 12280 0.65 18.5
HLN Haleon 11.35 12.61 11.12 19210698 52068 1.48 26.8
GSK GSK 41.03 44.46 8.36 5114530 84871 3.90 20.0
NVS Novartis 115.76 124.11 7.21 1673351 229089 3.45 18.1
TAK Takeda Pharmaceutical Co 15.03 15.40 2.49 2203412 48256 2.17 65.2
All data provided as at market close May 29, 2025.

Company Details

Merck & Co

MRK:NYS

Close Price

76.84

Our Valuation

154.49

% Difference

101.06

Market Cap ($M)

194482

P/E Ratio

11.2

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs.

Access the stockcalc valuation


Organon

OGN:NYS

Close Price

9.22

Our Valuation

14.97

% Difference

62.34

Market Cap ($M)

2406

P/E Ratio

3.2

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan.

Access the stockcalc valuation


Johnson & Johnson

JNJ:NYS

Close Price

155.21

Our Valuation

185.41

% Difference

19.46

Market Cap ($M)

376198

P/E Ratio

17.3

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Access the stockcalc valuation


Zoetis

ZTS:NYS

Close Price

168.63

Our Valuation

199.90

% Difference

18.54

Market Cap ($M)

75546

P/E Ratio

30.3

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Elanco Animal Health

ELAN:NYS

Close Price

13.44

Our Valuation

15.46

% Difference

15.01

Market Cap ($M)

6708

P/E Ratio

17.9

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries.

Access the stockcalc valuation


Dr Reddy's Laboratories

RDY:NYS

Close Price

14.72

Our Valuation

16.53

% Difference

12.28

Market Cap ($M)

12280

P/E Ratio

18.5

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr.

Access the stockcalc valuation


Haleon

HLN:NYS

Close Price

11.35

Our Valuation

12.61

% Difference

11.12

Market Cap ($M)

52068

P/E Ratio

26.8

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories.

Access the stockcalc valuation


GSK

GSK:NYS

Close Price

41.03

Our Valuation

44.46

% Difference

8.36

Market Cap ($M)

84871

P/E Ratio

20.0

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Access the stockcalc valuation


Novartis

NVS:NYS

Close Price

115.76

Our Valuation

124.11

% Difference

7.21

Market Cap ($M)

229089

P/E Ratio

18.1

Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Access the stockcalc valuation


Takeda Pharmaceutical Co

TAK:NYS

Close Price

15.03

Our Valuation

15.40

% Difference

2.49

Market Cap ($M)

48256

P/E Ratio

65.2

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Merck & Co and Organon are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-june-2025
Merck & Co $MRK and Organon $OGN are the most undervalued Drug Manufacturers stocks on the #NYS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-june-2025
Merck & Co and Organon are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-june-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.